[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523842":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Lukas K van Vugt, Drs.","CONTACT","0031 10 704 0704","l.k.vanvugt@erasmusmc.nl",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Erasmus MC","RECRUITING","Rotterdam","South Holland","3015 GD","Netherlands","NL",{"type":24,"coordinates":25},"Point",[26,27],4.47917,51.9225,{"lat":27,"lon":26},[30],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Lukas K. van Vugt","Research coordinator","100523842","reduced-dose-alemtuzumab-for-kidney-transplant-rejection-100523842",false,"NCT06100965","Reduced-dose Alemtuzumab for Kidney Transplant Rejection","The Effects of Reduced Dose Alemtuzumab for Severe Kidney Transplant Rejection","ROSETTE","Inclusion Criteria:\n\n* 18 years or older\n* Treatment for severe or glucocorticoid-resistant kidney transplant rejection with alemtuzumab.\n\nExclusion Criteria:\n\n* Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to treatment with alemtuzumab for the same rejection episode.\n* Recipients who have T cell counts below 200 × 106\u002FL before the start of therapy (for instance, because of lymphocyte depleting induction therapies).\n* Inability to provide written informed consent","ALL","18 Years",{"count":46,"type":47},25,"ESTIMATED","OBSERVATIONAL","Prospective, follow-up study of kidney transplant recipients treated with alemtuzumab anti-rejection therapy for severe or glucocorticoid-resistant kidney transplant rejection.",[51],"Kidney Transplant Rejection",[53],"alemtuzumab","2024-02-20",{"date":56,"type":57},"2024-02-21","ACTUAL",{"date":59,"type":57},"2023-12-01",{"date":61,"type":47},"2026-07-01",{"name":5,"class":6},1]